Breakthrough: Cabotegravir shows 88% reduction in HIV-1 incidence

In a significant leap forward in the fight against HIV, the Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to two
groundbreaking formulations of cabotegravir.

Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection are now authorized for preventing sexually transmitted HIV-1
infection in adults and adolescents weighing at least 35kg at increased risk.

This approval marks a pivotal moment in HIV (human immunodeficiency virus) prevention, offering an alternative to existing standard pre-exposure prophylaxis or
PrEP treatments.

HIV, a virus notorious for compromising the immune system, has long been a global health concern.

Cabotegravir, a member of the integrase inhibitor group, works by blocking a key enzyme necessary for the replication of HIV-1, thereby reducing the virus’s
ability to spread.